Ovarian cancer cost-effectiveness of therapy

Ovarian cancer Microchapters
Home
Patient Information
Overview
Historical Perspective
Classifications
Pathophysiology
Causes of Ovarian cancer
Differentiating Ovarian cancer from other Diseases
Epidemiology & Demographics
Risk Factors
Screening
Natural History, Complications & Prognosis
Diagnosis
History & Symptoms
Physical Examination
Staging
Laboratory Findings
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Ovarian cancer cost-effectiveness of therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Ovarian cancer cost-effectiveness of therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Ovarian cancer cost-effectiveness of therapy
CDC on Ovarian cancer cost-effectiveness of therapy
Ovarian cancer cost-effectiveness of therapy in the news
Blogs on Ovarian cancer cost-effectiveness of therapy
Directions to Hospitals Treating Ovarian cancer
Risk calculators and risk factors for Ovarian cancer cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: , Huda A. Karman, M.D.

Cost-effectiveness of therapy

• The management of ovarian cancer is composed of surgery and chemotherapy that can be either adjuvant or neoadjuvant depending on the stage and grade of the tumor and on the condition and function of the patient.
• Bevacizumab in addition to chemotherapy is a cost-effective alternative for ovarian cancer patients who are at high risk of progression